Campbell & CO Investment Adviser LLC Sells 46,288 Shares of NeoGenomics, Inc. $NEO

Campbell & CO Investment Adviser LLC trimmed its position in NeoGenomics, Inc. (NASDAQ:NEO) by 60.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 30,487 shares of the medical research company’s stock after selling 46,288 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in NeoGenomics were worth $235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Greenhouse Funds LLLP boosted its position in shares of NeoGenomics by 57.8% in the second quarter. Greenhouse Funds LLLP now owns 7,431,147 shares of the medical research company’s stock valued at $54,322,000 after acquiring an additional 2,722,823 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in NeoGenomics in the 2nd quarter worth about $6,071,000. First Light Asset Management LLC boosted its holdings in NeoGenomics by 13.3% in the 2nd quarter. First Light Asset Management LLC now owns 6,846,432 shares of the medical research company’s stock valued at $50,047,000 after purchasing an additional 803,610 shares during the period. Squarepoint Ops LLC grew its position in shares of NeoGenomics by 246.8% during the 2nd quarter. Squarepoint Ops LLC now owns 735,473 shares of the medical research company’s stock worth $5,376,000 after purchasing an additional 523,407 shares in the last quarter. Finally, HighMark Wealth Management LLC increased its holdings in shares of NeoGenomics by 221.3% during the third quarter. HighMark Wealth Management LLC now owns 400,334 shares of the medical research company’s stock worth $3,091,000 after purchasing an additional 275,734 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insiders Place Their Bets

In other NeoGenomics news, COO Warren Stone sold 22,128 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total transaction of $276,600.00. Following the sale, the chief operating officer owned 121,631 shares of the company’s stock, valued at approximately $1,520,387.50. The trade was a 15.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Alicia C. Olivo sold 20,916 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the transaction, the executive vice president owned 31,083 shares of the company’s stock, valued at $372,996. This trade represents a 40.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on NEO. Zacks Research upgraded NeoGenomics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 12th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 target price on shares of NeoGenomics in a research report on Monday, January 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. Leerink Partners set a $14.00 price target on NeoGenomics in a research report on Tuesday, October 28th. Finally, TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $12.00.

NeoGenomics Stock Down 1.2%

Shares of NASDAQ NEO opened at $12.81 on Friday. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -14.56 and a beta of 1.58. The company has a current ratio of 3.91, a quick ratio of 3.62 and a debt-to-equity ratio of 0.41. NeoGenomics, Inc. has a 12 month low of $4.72 and a 12 month high of $15.32. The stock has a 50-day moving average price of $12.09 and a two-hundred day moving average price of $9.44.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. The company had revenue of $187.80 million for the quarter, compared to the consensus estimate of $183.85 million. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period last year, the company posted $0.05 EPS. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. As a group, analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.